8月7日，康诺亚-B盘中上涨5.46%，报81.15港元，成交额6363.95万港元。
消息面上，近期多家机构密集增持该股。8月6日披露数据显示，东方证券于7月30日增持康诺亚-B约20.35万股，每股均价72.88港元，持股比例由4.98%升至5.05%，触及举牌线。此前高盛亦于7月13日增持28.75万股，持股比例升至5.00%。此外，公司核心产品CMG901全球III期临床试验CLARITY-Gastric01于7月28日取得积极顶线结果，在CLDN18.2阳性晚期胃癌患者中实现总生存期的统计学显著改善，安全性特征良好。机构增持与管线利好形成共振，推动股价走强。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.